Results 171 to 180 of about 12,874,292 (410)

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

Molecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu, Jianlei Zhao, Aaban Asfar Azmi, Avanti Gupte, Jenna Thibodeau, Shuang Liu, Jinli Yang, Guan Wang, Holly Edwards, Lisa A. Polin, Juiwanna Kushner, Sijana H. Dzinic, Kathryn White, Julie Boerner, Maik Hüttemann, Jay Yang, Yue Wang, Jeffrey W. Taub, Yubin Ge   +18 more
wiley   +1 more source

The Treatment of Liver Disease

AJN, American Journal of Nursing, 1953
LVER disease is increasing. Whereas previously it was seen mostly in conjunction with alcoholism or malnutrition, or as a complication of cholecystitis and cholelithiasis, additional causative factors are recognized today. The wide spread epidemic hepatitis of World War II, for instance, produced a sporadic inoculation of persons hitherto never exposed
openaire   +6 more sources

Peg-IFNα combined with hepatitis B vaccination contributes to HBsAg seroconversion and improved immune function

Virology Journal
Purpose The purpose of this study was to investigate immunological variations between a group that received the hepatitis B vaccine and a non-vaccine group. We focused on a cohort that achieved HBsAg seroclearance after Peg-IFNα treatment of CHB. Methods
Yisi Liu, Shan Ren, Lina Ma, Xiao Lin, Junfeng Lu, Zhenhuan Cao, Sujun Zheng, Zhongjie Hu, Xiaoxue Xu, Xinyue Chen   +9 more
doaj   +1 more source

CyTOF reveals platelet subtype changes predicting the efficacy of combined immunotherapy and targeted therapy in liver cancer

Frontiers in Immunology
IntroductionImmune checkpoint inhibitors combined with angiogenesis inhibitors are currently the first-line treatment for liver cancer. However, some patients still exhibit poor therapeutic outcomes.
Wenjing Wang, Dan Liu, Lilin Wang, Maimaitijiang Wubuli Aishan, Li Chen, Sujun Zheng, Junfeng Lu, Junfeng Lu   +7 more
doaj   +1 more source

GLYCOGEN REDUCTION IN CHICK LIVER DURING PULLORUM DISEASE [PDF]

, 1958
J. A. Cameron, D. Frank Holtman, C. D. Jeffries   +2 more
openalex   +1 more source

Expression and function of osteopontin variants in HCV-related liver disease and hepatocellular carcinoma. [PDF]

, 2010
Osteopontin (OPN) is a highly secreted multi-functional sialoprotein that is widely expressed in tissues, blood and urine. It is involved in a number of normal physiological functions, but is also significantly elevated in a number of cancers.
Phillips, Renee Jade
core   +1 more source

The ACCEPTance of automation: refining circulating tumor cells enumeration for improved metastatic colorectal cancer prognosis

Molecular Oncology, EarlyView.
This study highlights the potential of automated enumeration using the ACCEPT software to refine circulating tumor cell (CTC) detection in metastatic colorectal cancer (mCRC). The automated method demonstrates improved accuracy and reduced variability compared to the manual approach.
Michela De Meo, Marco Siringo, Alessandro Vici, Ann Zeuner, Orietta Gandini, Paola Gazzaniga, Chiara Nicolazzo   +6 more
wiley   +1 more source

Alcoholic Liver Disease

Medical Clinics of North America, 1989
Alcohol has been implicated in the genesis of liver disease for centuries. Significant progress has been made in our understanding of the pathogenesis of ALD. It is now apparent that both the consumption and the metabolism of alcohol promote the production of inflammatory mediators (cytokines) that result in hepatotoxicity and fibrogenesis.
openaire   +3 more sources

Liver cirrhosis-epidemiological and Clinical Aspects [PDF]

, 2008
Liver cirrhosis is the end-stage of many different chronic liver diseases. Limited data exists on the epidemiology, natural history and complications of liver cirrhosis such as esophageal varices and malignancies in the Nordic countries after the ...
Gunnarsdóttir, Steingerður Anna
core  

Adaptaquin is selectively toxic to glioma stem cells through disruption of iron and cholesterol metabolism

Molecular Oncology, EarlyView.
Adaptaquin selectively kills glioma stem cells while sparing differentiated brain cells. Transcriptomic and proteomic analyses show Adaptaquin disrupts iron and cholesterol homeostasis, with iron chelation amplifying cytotoxicity via cholesterol depletion, mitochondrial dysfunction, and elevated reactive oxygen species.
Adrien M. Vaquié, Davod R. Shah, Eliane E. S. Brechbühl, Michael McNicholas, Zhaoyang Xu, John H. Stockley, Laura Morcom, Diana Gold Diaz, Gemma C. Girdler, Rachel V. Seear, Gabriel Balmus, Rajiv R. Ratan, Harry Bulstrode, James A. Nathan, Manav Pathania, Kevin M. Brindle, David H. Rowitch   +16 more
wiley   +1 more source